Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1973 2
1975 1
1978 2
1979 2
1980 1
1981 1
1982 1
1983 3
1984 1
1985 9
1986 10
1987 9
1988 13
1989 11
1990 16
1991 20
1992 14
1993 12
1994 16
1995 15
1996 17
1997 17
1998 20
1999 18
2000 10
2001 15
2002 16
2003 25
2004 12
2005 24
2006 15
2007 14
2008 20
2009 20
2010 31
2011 22
2012 38
2013 51
2014 58
2015 59
2016 48
2017 51
2018 57
2019 53
2020 66
2021 60
2022 56
2023 56
2024 56
2025 68
2026 23

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,115 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Fidaxomicin versus vancomycin for Clostridium difficile infection.
Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK; OPT-80-003 Clinical Study Group. Louie TJ, et al. N Engl J Med. 2011 Feb 3;364(5):422-31. doi: 10.1056/NEJMoa0910812. N Engl J Med. 2011. PMID: 21288078 Free article. Clinical Trial.
Patients generally have a response to oral vancomycin or metronidazole; however, the rate of recurrence is high. This phase 3 clinical trial compared the efficacy and safety of fidaxomicin with those of vancomycin in treating C. difficile infection. ...The rates of …
Patients generally have a response to oral vancomycin or metronidazole; however, the rate of recurrence is high. This phase 3 clinica …
Risk factors for vancomycin-associated acute kidney injury: A systematic review and meta-analysis.
Kim JY, Yee J, Yoon HY, Han JM, Gwak HS. Kim JY, et al. Br J Clin Pharmacol. 2022 Sep;88(9):3977-3989. doi: 10.1111/bcp.15429. Epub 2022 Jun 15. Br J Clin Pharmacol. 2022. PMID: 35665530 Free article.
For patient factors, black race (OR 1.47, 95% CI: 1.16-1.87), Caucasian (OR 0.72, 95% CI: 0.58-0.90) and obesity (OR 1.46, 95% CI: 1.12-1.90) were associated with an increase in vancomycin-associated AKIs. In terms of vancomycin-related factors, longer treatment dur …
For patient factors, black race (OR 1.47, 95% CI: 1.16-1.87), Caucasian (OR 0.72, 95% CI: 0.58-0.90) and obesity (OR 1.46, 95% CI: 1.12-1.90 …
Fecal Microbiota Transplantation Versus Vancomycin for Primary Clostridioides difficile Infection : A Randomized Controlled Trial.
Juul FE, Bretthauer M, Johnsen PH, Samy F, Tonby K, Berdal JE, Hoff DAL, Ofstad EH, Abraham A, Seip B, Wiig H, Rognstad ØB, Glad IF, Valeur J, Nissen-Lie AE, Ness-Jensen E, Lund KMA, Skjevling LK, Hanevik K, Skudal H, Melsom EJ, Boyar R, Cooper TJ, Ranheim TE, Riise EM, Adami HO, Kalager M, Løberg M, Garborg KK. Juul FE, et al. Ann Intern Med. 2025 Jul;178(7):940-947. doi: 10.7326/ANNALS-24-03285. Epub 2025 Jun 17. Ann Intern Med. 2025. PMID: 40523286 Clinical Trial.
RESULTS: Of 104 randomly assigned patients, 100 received FMT or the first dose of vancomycin and were eligible for analysis. Clinical cure and no disease recurrence within 60 days without additional treatment was observed in 34 of 51 patients (66.7%) with FMT versus 30 of …
RESULTS: Of 104 randomly assigned patients, 100 received FMT or the first dose of vancomycin and were eligible for analysis. Clinical …
Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: Systematic review and meta-analysis.
Abdelmessih E, Patel N, Vekaria J, Crovetto B, SanFilippo S, Adams C, Brunetti L. Abdelmessih E, et al. Pharmacotherapy. 2022 Sep;42(9):741-753. doi: 10.1002/phar.2722. Epub 2022 Aug 5. Pharmacotherapy. 2022. PMID: 35869689 Free PMC article.
Vancomycin is commonly used to treat methicillin-resistant Staphylococcus aureus infections and is known to cause nephrotoxicity. Previous Vancomycin Consensus Guidelines recommended targeting trough concentrations but the 2020 Guidelines suggest monitoring vanco …
Vancomycin is commonly used to treat methicillin-resistant Staphylococcus aureus infections and is known to cause nephrotoxicity. Pre …
Epidemiology and outcomes of vancomycin-resistant enterococcus infections: a systematic review and meta-analysis.
Eichel VM, Last K, Brühwasser C, von Baum H, Dettenkofer M, Götting T, Grundmann H, Güldenhöven H, Liese J, Martin M, Papan C, Sadaghiani C, Wendt C, Werner G, Mutters NT. Eichel VM, et al. J Hosp Infect. 2023 Nov;141:119-128. doi: 10.1016/j.jhin.2023.09.008. Epub 2023 Sep 19. J Hosp Infect. 2023. PMID: 37734679 Free article.
Vancomycin-resistant enterococci (VRE) cause many infections in the healthcare context. Knowledge regarding the epidemiology and burden of VRE infections, however, remains fragmented. ...In contrast to previous findings, our meta-analysis of included studies indicates that …
Vancomycin-resistant enterococci (VRE) cause many infections in the healthcare context. Knowledge regarding the epidemiology and burd …
Efficacy of fidaxomicin versus vancomycin in the treatment of Clostridium difficile infection: A systematic meta-analysis.
Zhao Z, Wu Y, Geng X, Yuan C, Fu Y, Yang G. Zhao Z, et al. Medicine (Baltimore). 2024 Aug 9;103(32):e39213. doi: 10.1097/MD.0000000000039213. Medicine (Baltimore). 2024. PMID: 39121324 Free PMC article.
RESULTS: Results showed that there was no significant difference in the overall efficacy of the treatment between fidaxomicin and vancomycin, and results in the subgroups of CDI hypervirulent strains and recurrent CDI were obtained, but vancomycin was more effective …
RESULTS: Results showed that there was no significant difference in the overall efficacy of the treatment between fidaxomicin and vancomy …
Comparative effectiveness of daptomycin versus vancomycin among patients with methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections: A systematic literature review and meta-analysis.
Adamu Y, Puig-Asensio M, Dabo B, Schweizer ML. Adamu Y, et al. PLoS One. 2024 Feb 21;19(2):e0293423. doi: 10.1371/journal.pone.0293423. eCollection 2024. PLoS One. 2024. PMID: 38381737 Free PMC article.
CONCLUSION: Compared with vancomycin, an early switch from vancomycin to daptomycin was significantly associated with lower odds of mortality. ...Therefore, the efficacy of early daptomycin use over vancomycin against mortality among MRSA BSIs patients may ad …
CONCLUSION: Compared with vancomycin, an early switch from vancomycin to daptomycin was significantly associated with lower od …
Vancomycin combined with piperacillin/tazobactam increases the risk of acute kidney injury compared with vancomycin plus other anti-pseudomonal beta-lactams: a systematic review and network meta-analysis.
Pan K, Li R, Li Y, Ding X, Li X, Lv Q. Pan K, et al. J Antimicrob Chemother. 2025 Jan 3;80(1):47-58. doi: 10.1093/jac/dkae410. J Antimicrob Chemother. 2025. PMID: 39533846
Network meta-analysis indicated that vancomycin plus piperacillin/tazobactam was associated with significantly higher AKI risk than vancomycin plus cefepime (OR 2.55, 95% CI 2-3.28), vancomycin plus meropenem (OR 2.26, 95% CI 1.71-3.02) and vancomycin …
Network meta-analysis indicated that vancomycin plus piperacillin/tazobactam was associated with significantly higher AKI risk than …
Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial.
Guery B, Menichetti F, Anttila VJ, Adomakoh N, Aguado JM, Bisnauthsing K, Georgopali A, Goldenberg SD, Karas A, Kazeem G, Longshaw C, Palacios-Fabrega JA, Cornely OA, Vehreschild MJGT; EXTEND Clinical Study Group. Guery B, et al. Lancet Infect Dis. 2018 Mar;18(3):296-307. doi: 10.1016/S1473-3099(17)30751-X. Epub 2017 Dec 19. Lancet Infect Dis. 2018. PMID: 29273269 Clinical Trial.
FINDINGS: Between Nov 6, 2014, and May 5, 2016, 364 patients were enrolled and randomly assigned to receive extended-pulsed fidaxomicin or vancomycin. 362 patients received at least one dose of study medication (181 in each group). 124 (70%) of 177 patients in the modified …
FINDINGS: Between Nov 6, 2014, and May 5, 2016, 364 patients were enrolled and randomly assigned to receive extended-pulsed fidaxomicin or …
Oral Vancomycin for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial.
Keating JA, Xu T, Graham MB, Ramesh M, Khanna S, Dixon J, Kates A, Haight K, Zhao J, Saddler C, Safdar N. Keating JA, et al. JAMA Netw Open. 2025 Jul 1;8(7):e2517834. doi: 10.1001/jamanetworkopen.2025.17834. JAMA Netw Open. 2025. PMID: 40601321 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate whether oral vancomycin prophylaxis compared with placebo is effective against recurrent CDI during and 8 weeks after the end of study treatment. ...Adverse events occurred in 27 of 39 participants in the oral vancomycin group (69.2%) and 27 o …
OBJECTIVE: To evaluate whether oral vancomycin prophylaxis compared with placebo is effective against recurrent CDI during and 8 week …
1,115 results